World class potential in developing new pharmaceutical products
his week's discussion topic
I. Tiny biotech with world class potential trading well below cash value
Thallion Pharmaceuticals (TSX: T.TLN, Stock Forum; 12 cents)
www.thallion.com
Shares outstanding: 32 million/ Market cap: $3.8 million
Cash & investments Aug 31: $9 million (28 cents/share)
Debt: $1.8 million ($ - 0.06/share)
Thallion is an unknown, thinly-traded biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology, with a current emphasis on the development and commercialization of Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli (“STEC”) bacterial infections).
Continue reading the article.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: General
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in